Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4456235 | 1.00 | MAPT (0.42) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3934049 | 0.83 | MAPT (0.38) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3933201 | 0.82 | MAPT (0.37) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3934048 | 0.80 | MAPT (0.38) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3933193 | 0.79 | MAPT (0.37) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| Bromide SCHEMBL4455466 | 0.76 | MAPT (0.57) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| Bromide SCHEMBL4455472 | 0.76 | MAPT (0.57) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3934653 | 0.72 | MAPT (0.37) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3943122 | 0.72 | MAPT (0.37) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3934652 | 0.70 | MAPT (0.37) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488353-B2 | Cationic heteroarylazine dyes and colorants containing these compounds | WELLA AG (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20070174975-A1 | Cationic heteroarylazine dyes and colorants containing these compounds | Wella GmbH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1718705-A1 | CATIONIC HETEROARYL AZINE DYES, AND DYEING AGENTS CONTAINING SAID COMPOUNDS | Wella Aktiengesellschaft (DE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005083009-A1 | CATIONIC HETEROARYL AZINE DYES, AND DYEING AGENTS CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070174975-A1 | Cationic heteroarylazine dyes and colorants containing these compounds | KRT18, IK, CRYZ | ACHE 2915/4885MAPT 1057/4885MEN1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.